CAMBRIDGE, Mass., April 13, 2022 /PRNewswire/ — Flagship Pioneering, the bioplatform innovation firm, introduced in the present day that Michael Severino, M.D., is becoming a member of the corporate as CEO-Associate. Dr. Severino joins Flagship from AbbVie, Inc. the place he served as Vice Chairman and President. As a CEO-Associate, Dr. Severino will play an instrumental position in Flagship Pioneering’s efforts to create and develop groundbreaking improvements in human well being and can function CEO of a Flagship firm to be introduced sooner or later.
With greater than 20 years of biopharmaceutical management, Dr. Severino has made vital contributions to the analysis, improvement, registration, and commercialization of greater than a dozen authorized therapies. In his eight years with AbbVie, he led efforts to construct a robust pipeline and advance promising science for sufferers within the areas of hematologic oncology, immunology, and neuroscience. As Senior Vice President, International Growth and Company Chief Medical Officer at Amgen, Inc. he led a company of greater than 2,000 individuals in 35 nations and oversaw the corporate’s R&D efforts throughout all therapeutic areas, together with oncology, irritation neuroscience, and metabolic issues. Previous to becoming a member of Amgen, Dr. Severino was Senior Director at Merck & Co., Inc. the place he was chargeable for main analysis in a number of areas, together with scientific genomics, molecular profiling, and experimental drugs.
“Mike’s stellar management in biopharmaceutical technique and R&D can be a superb addition to Flagship and our ecosystem of corporations, and I’m happy to welcome him to our staff,” mentioned Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. “With a observe document of creating revolutionary methods, driving scientific, operational, and enterprise excellence, and main transformational change, Mike is a perfect match for Flagship, the place we invent, develop, and scale breakthrough improvements that enhance lives.”
“I’m thrilled to tackle this position and companion with the high-caliber staff of world-class scientists, technologists, and enterprise executives assembled by Flagship Pioneering,” mentioned Dr. Michael Severino. “I sit up for making use of my expertise throughout all phases of drug discovery, improvement, and commercialization at Flagship, to assist make an essential distinction for sufferers.”
Dr. Severino’s appointment follows latest govt appointments to Flagship Pioneering together with: Michelle C. Werner, CEO-Associate and CEO of Alltrna; Margo Georgiadis, CEO-Associate; Tom DiLenge, Senior Associate, International Coverage, Regulatory & Governmental Technique; Vaithianathan “Palani” Palaniappan, Chief Expertise Officer of Pioneering Medicines; Justine Levin-Allerhand, Senior Associate, Company Growth; Kathy Biberstein, Common Counsel and Govt Associate; and Dr. Stephen Hahn, CEO-Associate and CEO of Harbinger Well being, amongst others.
About Michael Severino, M.D.
Michael Severino is an completed govt with greater than 20 years of management expertise within the biopharmaceutical trade and has made vital contributions to the event, registration, and/or commercialization of greater than a dozen authorized therapies. He joined AbbVie in 2014 as EVP of R&D and Chief Scientific Officer and was promoted to Vice Chairman and President in 2018. In that capability, he assumed management of capabilities together with Enterprise Growth and Company Technique whereas sustaining general accountability for R&D. In his eight years with AbbVie, Dr. Severino led efforts to construct a robust pipeline and advance promising science for sufferers within the areas of hematologic oncology, immunology, and neuroscience.
Previous to becoming a member of AbbVie in 2014, Dr. Severino was Senior Vice President, International Growth and Company Chief Medical Officer at Amgen, Inc. Throughout his tenure at Amgen, he served in a number of management positions, together with VP, International Growth; VP, Therapeutic Space Head, Common Medication and Irritation; and Therapeutic Space Head, Irritation International Medical Growth. As Senior Vice President he led a company of greater than 2,000 individuals in 35 nations and oversaw the corporate’s R&D efforts throughout all therapeutic areas, together with oncology, irritation neuroscience and metabolic issues. Previous to becoming a member of Amgen, Dr. Severino was Senior Director at Merck & Co., Inc. the place he was chargeable for main analysis in a number of areas, together with scientific genomics, molecular profiling, and experimental drugs.
Dr. Severino earned his Bachelor of Science in Biochemistry from the College of Maryland, Faculty Park, the place he graduated summa cum laude in 1987 and was a member of the Phi Beta Kappa Society. In 1993, he earned his M.D. from the Johns Hopkins College, the place he was a member of the Alpha Omega Alpha Honor Medical Society. Dr. Severino accomplished his residency and post-doctoral coaching at Massachusetts Common Hospital and Harvard Medical Faculty.
About Flagship Pioneering
Flagship Pioneering conceives, creates, sources, and develops first-in-category bioplatform corporations to remodel human well being and sustainability. Since its launch in 2000, the agency has, by way of its Flagship Labs unit, utilized its distinctive hypothesis-driven innovation course of to originate and foster greater than 100 scientific ventures, leading to greater than $140 billion in mixture worth. So far, Flagship has deployed over $2.6 billion in capital towards the founding and progress of its pioneering corporations alongside greater than $19 billion of follow-on investments from different establishments. The present Flagship ecosystem includes 42 transformative corporations, together with Axcella Therapeutics (NASDAQ: AXLA), Codiak Biosciences (NASDAQ: CDAK), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ: SGTX).
SOURCE Flagship Pioneering